Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement

This prospective, single-center, single-arm, open-label pilot clinical study investigates the efficacy and safety of high-dose oral 35 kDa hyaluronan (HA35) for improving facial contour, reducing subcutaneous fullness, alleviating inflammatory erythema, enhancing facial vitality, and supporting body weight management.

Eligible subjects will take 5 g of oral HA35 once daily in the morning on an empty stomach for 40 consecutive days. Outcome assessments will be performed at baseline, Day 7, Day 14, Day 28, and Day 40 using a validated 0-10 Visual Analog Scale (VAS) to evaluate subcutaneous fat reduction, erythema improvement, facial vitality, and gastrointestinal tolerance. Body weight will be measured at each time point.

Safety evaluations include monitoring of adverse events, gastrointestinal comfort, dry eye symptoms, and overall tolerability.

This is a non-invasive, oral, non-pharmacological intervention with minimal risk to participants. All procedures will be conducted in accordance with the Declaration of Helsinki, and written informed consent will be obtained from all subjects prior to enrollment.

• High-Dose Oral 35 kDa Hyaluronan (HA35) (Device), also known as Oral HA35, 35 kDa Hyaluronan: Oral powder formulation containing high-purity35 kDa hyaluronan fragments (20-80 kDa), 5 g per day, administered orally on an empty stomach for 40 days to improve facial contour, reduce subcutaneous fullness, alleviate erythema, and enhance facial vitality.

Primary outcomes

• Change in Facial Subcutaneous Fullness VAS Score (0-10) [Baseline to Day 40]: Change in cheek fullness and double chin prominence measured by 0-10 VAS, 0 = no improvement, 10 = maximum improvement.

Secondary outcomes

• Change in Body Subcutaneous Fullness Severity (0-10 VAS Score) [Baseline to Day 40]: Change in body subcutaneous fullness severity, assessed using a 0-10 Visual Analog Scale (VAS), where 0 = no fullness and 10 = maximum perceived subcutaneous fullness.
• Change in Facial Inflammatory Erythema Severity (0-10 VAS Score) [Baseline to Day 7 and Day 40]: Change in facial inflammatory erythema severity, assessed using a 0-10 Visual Analog Scale (VAS), where 0 = no erythema and 10 = maximum redness.
• Change in Facial Vitality (0-10 VAS Score) [Baseline to Day 7 and Day 40]: Change in perceived facial vitality and skin radiance, assessed using a 0-10 Visual Analog Scale (VAS), where 0 = dull/lifeless and 10 = vibrant/healthy appearance.
• Change in body weight (kg) [Baseline to Day 40]: Change in body weight measured in kilograms (kg) using a calibrated digital scale, taken at the same time of day under consistent conditions.
• Incidence and Severity of Treatment-Related Adverse Events [From baseline to the end of the 40-day intervention period]: Number and severity of adverse events reported during the study, including gastrointestinal discomfort, allergic reactions, or other systemic effects. Severity is graded using the Common Terminology Criteria for Adverse Events (CTCAE).
• Gastrointestinal Tolerability (0-10 VAS Score) [From baseline to the end of the 40-day intervention period]: Subject-reported gastrointestinal tolerability, assessed using a 0-10 Visual Analog Scale (VAS), where 0 = no discomfort and 10 = severe gastrointestinal distress (e.g., bloating, nausea).

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria:

* Age 18-60 years, male or female
* Seeking non-invasive improvement of facial/body appearance
* Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin
* Ability to complete VAS assessments and study logs
* Signed written informed consent

Exclusion Criteria:

* Aesthetic/weight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks
* Significant weight change (>3 kg) within 3 months
* Uncontrolled systemic disease (diabetes, hypertension, etc.)
* Known hypersensitivity to hyaluronan
* Pregnant or lactating women
* Participation in another clinical trial within 30 days